The Cystic Fibrosis Foundation has awarded more than $23 million across 11 sites in its Research Development Program (RDP), a network of research centers that brings together top-notch scientists from different disciplines to apply their expertise to the challenges of treating cystic fibrosis.
Site Search
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
Because of the wide variety of mental health concerns and needs of the CF population, the Cystic Fibrosis Foundation has formed the Prioritizing Research in Mental Health (PRIME) Working Group, which is dedicated to mental health research.
The Cystic Fibrosis Foundation is requesting applications with a letter of intent for innovative registry-based analyses that aim to test novel methods to advance the use of the Foundation’s Patient Registry.
Revised Law Includes Designated Funding for Rare Diseases
The Cystic Fibrosis Foundation recently hosted the CFF Research Conference: Pushing the Frontiers, bringing together nearly 150 basic scientists, clinical researchers, graduate students and pharmaceutical company representatives to share information on recent advances and critical challenges in CF drug discovery and development.
The top priority in clinical research is protecting the safety of people who participate. Learn more about the numerous layers of review that help keep participants safe.
The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.
The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.